Drugs / CLL-1, CD33 and/or CD123-specific CAR gene-engineered T cells
CLL-1, CD33 and/or CD123-specific CAR gene-engineered T cells
also known as
CLL1+CD33 CAR-T · CLL1 and CD38 dual-target CAR-T · CLL1 and CD38 Dual-Target CAR-T Cell Injection
Cell therapy targets CD33, CD38
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT06110208 | Oct 2023 → Jul 2024 | acute myeloid leukemia | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China | Terminated | No outcome recorded |
| Phase 12 trials | ||||||
| Phase 1 | NCT06880354 | May 2025 → Mar 2028 expected | acute myeloid leukemia | Institute of Hematology & Blood Diseases Hospital, China | Recruiting | No outcome recorded |
| Phase 1 | NCT05467254 | Aug 2022 → Aug 2024 | acute myeloid leukemia | Zhejiang University | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04010877 | Aug 2025 → Jul 2028 expected | acute myeloid leukemia | Shenzhen Geno-Immune Medical Institute | Recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT05943314 | Jul → Aug 2023 | acute myeloid leukemia | Guangzhou Bio-gene Technology Co., Ltd | Withdrawn | No outcome recorded Stop: Business |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CLL-1, CD33 and/or CD123-specific CAR gene-engineered T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04010877 ↗ |
| Known as | CLL1 and CD38 dual-target CAR-T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06110208 ↗ |
| Known as | CLL1 and CD38 Dual-Target CAR-T Cell Injection | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06880354 ↗ |
| Known as | CLL1+CD33 CAR-T | “CLL1/+CD33 CAR T is a type of CAR T cell therapy for patients with treating/relapsed acute myeloid leukemia.” NCT05943314 ↗ |
| Action | Deplete | “CD33 and CD123 CAR T cells can eradicate AML” NCT04010877 ↗ |
| Modality | Cell therapy | “CAR T cells” NCT04010877 ↗ |
| Route | Intravenous | “applied to patients through intravenous delivery” NCT04010877 ↗ |
| Target | CD33 | “anti-CLL1 /+CD33 CAR T cells” NCT05943314 ↗ |